Mechanistic Studies on Staphylococcal Quorum Quenching Natural Products

葡萄球菌群体淬灭天然产物的机理研究

基本信息

  • 批准号:
    8499274
  • 负责人:
  • 金额:
    $ 35.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Staphylococcus aureus is a highly problematic pathogen. Rates of infection in both the community and healthcare setting are on the rise, and coupled with its highly antibiotic-resistant nature, this makes S. aureus a top public health concern. In fact, invasive methicillin-resistant S. aureus (MRSA) is responsible for more deaths in the USA than AIDS. Nevertheless, the number of new antibiotic leads in the pipeline is diminishing, and many scientists have put out a call for the discovery and development of a new class of drugs which could mediate microbial pathogenicity rather than growth and survival. The staphylococcal quorum-sensing pathway, controlled by the accessory gene regulator (agr) system, is a potential target for such anti-pathogenic drug discovery efforts, as it serves as a global regulator of staphylococcal virulence. Following extensive studies on the complementary and alternative medical (CAM) practices of southern Italians in the treatment of skin and soft tissue infection, over 100 plant samples were identified, collected, extracted, and examined for their anti-staphylococcal potential. Among the tests included was a screen for the inhibition of??-hemolysin, a translational protein product of RNAIII, whose production is regulated through the agr quorum-sensing pathway. Extract 134, which is derived from a popular tree with edible fruits and medicinal leaves and bark, was found to exhibit a strong dose-dependent inhibition of ?-hemolysin at sub-inhibitory concentrations for growth. The dose-dependent quorum-quenching effects of Extract 134 were confirmed through the use of fluorescent genetic reporters for agr (types I-IV). This activity is important based upon previous animal studies with agr knockout mutants that show a diminished capacity to initiate and persist in a skin infection model. In the proposed study, we seek to improve our understanding of the mechanistic basis for Extract 134's quorum-quenching effects and evaluate the therapeutic relevance of such an anti-virulence therapy using in vivo models. The study will address four specific aims: 1) identification and structural elucidation of the active constituent(s) (or marker compounds for standardization) in Extract 134; 2) elucidation of the mechanism of action for the quorum-quenching effects observed; 3) determination of drug metabolism and pharmacokinetic parameters (DM/PK) of the bioactive constituent(s); and 4) evaluation of efficacy in treating S. aureus skin infection in a murine model.
描述(申请人提供):金黄色葡萄球菌是一种极具问题的病原体。在社区和医疗保健环境中的感染率都在上升,再加上它对抗生素的高度抗药性,这使得金黄色葡萄球菌成为首要的公共卫生问题。事实上,侵袭性耐甲氧西林金黄色葡萄球菌(MRSA)在美国造成的死亡人数超过艾滋病。然而,正在研发的新抗生素的数量正在减少,许多科学家呼吁发现和开发一类新的药物,这种药物可以介导微生物的致病性,而不是生长和生存。葡萄球菌群体感应通路由辅助基因调节系统(AGR)控制,是此类抗病原性药物发现努力的潜在靶点,因为它是葡萄球菌毒力的全球调节因子。在对意大利南部人治疗皮肤和软组织感染的补充和替代医疗(CAM)实践进行广泛研究后,对100多个植物样本进行了鉴定、收集、提取和抗葡萄球菌潜力检测。在这些测试中,包括了对β-溶血素的抑制筛选,?-溶血素是RNAIII的一种翻译蛋白产物,其产生通过agr群体感应途径进行调节。提取物134是从一种常见的树中提取的,含有可食用的果实和药用叶和树皮,发现在亚抑制浓度下对β-溶血素具有很强的剂量依赖性抑制作用。通过对AGR(类型I-IV)的荧光遗传报告的使用,证实了提取物134的剂量依赖的群体猝灭效应。这一活动是重要的,基于先前对agr基因敲除突变体的动物研究,这些突变体表明启动和维持皮肤感染模型的能力减弱。在这项拟议的研究中,我们试图提高我们对提取物134‘S群体猝灭作用的机制基础的理解,并使用体内模型评估这种抗毒力疗法的治疗相关性。这项研究将致力于四个具体目标:1)鉴定和结构鉴定提取物134中的活性成分(S)(或标准化标记化合物);2)阐明观察到的群体猝灭效应的作用机制;3)测定活性成分(S)的药物代谢和药代动力学参数(Dm/Pk);以及4)在小鼠模型上评价治疗金黄色葡萄球菌皮肤感染的疗效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cassandra Leah Quave其他文献

Cassandra Leah Quave的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cassandra Leah Quave', 18)}}的其他基金

Mechanistic Studies on Staphylococcal Quorum Quenching Natural Products
葡萄球菌群体淬灭天然产物的机理研究
  • 批准号:
    8369528
  • 财政年份:
    2012
  • 资助金额:
    $ 35.48万
  • 项目类别:
Mechanistic Studies on Staphylococcal Quorum Quenching Natural Products
葡萄球菌群体淬灭天然产物的机理研究
  • 批准号:
    8854031
  • 财政年份:
    2012
  • 资助金额:
    $ 35.48万
  • 项目类别:
Mechanistic Studies on Staphylococcal Quorum Quenching Natural Products
葡萄球菌群体淬灭天然产物的机理研究
  • 批准号:
    9096696
  • 财政年份:
    2012
  • 资助金额:
    $ 35.48万
  • 项目类别:
Mechanistic Studies on Staphylococcal Quorum Quenching Natural Products
葡萄球菌群体淬灭天然产物的机理研究
  • 批准号:
    8688153
  • 财政年份:
    2012
  • 资助金额:
    $ 35.48万
  • 项目类别:
Anti-biofilm activity of white horehound extract in catheter-associated infection
白苦海草提取物在导管相关感染中的抗生物膜活性
  • 批准号:
    7872930
  • 财政年份:
    2009
  • 资助金额:
    $ 35.48万
  • 项目类别:
Anti-biofilm activity of white horehound extract in catheter-associated infection
白苦海草提取物在导管相关感染中的抗生物膜活性
  • 批准号:
    8007412
  • 财政年份:
    2009
  • 资助金额:
    $ 35.48万
  • 项目类别:
Anti-biofilm activity of white horehound extract in catheter-associated infection
白苦海草提取物在导管相关感染中的抗生物膜活性
  • 批准号:
    7615878
  • 财政年份:
    2009
  • 资助金额:
    $ 35.48万
  • 项目类别:
Anti-pathogenic activity of natural products from plants against MRSA
植物天然产物对 MRSA 的抗病原体活性
  • 批准号:
    7504785
  • 财政年份:
    2007
  • 资助金额:
    $ 35.48万
  • 项目类别:
Anti-pathogenic activity of natural products from plants against MRSA
植物天然产物对 MRSA 的抗病原体活性
  • 批准号:
    7409887
  • 财政年份:
    2007
  • 资助金额:
    $ 35.48万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 35.48万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 35.48万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 35.48万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 35.48万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 35.48万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 35.48万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 35.48万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 35.48万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 35.48万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 35.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了